Notice: You are only receiving the textual content of this site, most likely because you are using an outdated web browser that does not support a web technology called CSS. To also receive this site's layout and design, please upgrade to a browser that supports web standards.


The Wagner Lab

P-sel-Ig treatment of hemophilia A mice generates procoagulant microparticles and accelerates the onset of clotting

P-sel-Ig treatment of hemophilia A mice generates procoagulant microparticles and accelerates the onset of clotting. Representative curves showing the whole blood clotting process in F8-/- mice after a 72 h treatment with P-sel-Ig(right) or control immunoglobulin (left). 'Clot signal', which represents resistance encountered by a moving probe, increases as fibrin polymerizes and decreases when clot retracts.

Ref: Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 9: 1020-1025, 2003.



WAGNER LAB/CBR/HMS © 2003–2004 | XHTML 1.0-T, CSS